Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827257 | 1.00 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL24851661 | 0.85 | KDM4E (0.39) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12229216 | 0.82 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16589048 | 0.82 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL24004392 | 0.80 | ACE (0.38) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL21566849 | 0.75 | SIRT6 (0.52) | — | |
| SCHEMBL20196315 | 0.75 | SIRT6 (0.52) | — | |
| SCHEMBL12128766 | 0.75 | ALDH1A1 (0.35) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL21846792 | 0.74 | KDM4E (0.65) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9962914 | 0.73 | KDM4E (0.71) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218407-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-07-04 | — | — | US | disclosed |
| US-11926857-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20210277432-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-09-09 | — | — | US | disclosed |
| US-11046982-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10793884-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200157588-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10590445-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180355391-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2018-12-13 | — | — | US | disclosed |
| US-20180187225-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2018-07-05 | — | — | US | disclosed |
| US-9970037-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-15 | — | — | US | disclosed |
| US-8383382-B2 | Variant LovD polypeptides and their uses | CODEXIS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120315680-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2483292-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | Codexis, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8211664-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2032715-B1 | Methods and materials for making simvastatin and related compounds | UNIV CALIFORNIA (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110111468-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | CODEXIS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011041231-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | CODEXIS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20090191602-A1 | Methods and Materials for Making Simvastatin and Related Compounds | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2009-07-30 | — | — | US | disclosed |
| EP-2032715-A2 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | The Regents of the University of California (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007139871-A2 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590445-B2 | Variant LovD polypeptides and their uses | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
| US-11046982-B2 | Variant LovD polypeptides and their uses | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
| US-20210277432-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
| US-11926857-B2 | Variant LovD polypeptides and their uses | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
| US-20200157588-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
| US-20180187225-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
| US-20110111468-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | PCSK9, HMGCR, LCAT | KDM4E 3776/4885MAPT 1615/4885THRB 2600/4885 |
| US-20240218407-A1 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | LCAT, HMGCR, FNTA | KDM4E 3524/4885MAPT 1655/4885THRB 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.